SeekingAlpha · Aug 16, 2026
SK
NASDAQ · SKYE
Skye Bioscience, Inc.
Healthcare · Biotechnology
$0.28
Down-$0.00 (-0.14%)
Updated Aug 22, 2026, 1:34 PM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.01M
- P/E ratio
- -1.08
- Dividend yield
- 0.00%
- 52-week range
- $0.28 – $1.12
- Volume
- 974.58K
- Avg. volume
- 819.32K
Price performance
SKYE price history
1M range · 21 trading sessions · Daily adjusted prices
SKYE closed at $0.28 after 21 trading sessions, down 57.05% for the selected period.
- Last close
- $0.28
- Period change
- -57.05%
- Period low
- $0.28
- Period high
- $0.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.2804 | $0.284 | $0.255 | $0.28 | 974.58K |
| Aug 20, 2026 | $0.303 | $0.325 | $0.276 | $0.2804 | 1.6M |
| Aug 19, 2026 | $0.341 | $0.3777 | $0.30 | $0.3059 | 1.39M |
| Aug 18, 2026 | $0.3847 | $0.4452 | $0.35 | $0.359 | 1.82M |
| Aug 17, 2026 | $0.5703 | $0.5857 | $0.4128 | $0.4151 | 9.44M |
| Aug 14, 2026 | $0.86 | $0.88 | $0.4732 | $0.5015 | 6.6M |
| Aug 13, 2026 | $0.541 | $0.55 | $0.5333 | $0.541 | 37.5K |
| Aug 12, 2026 | $0.5465 | $0.55 | $0.5302 | $0.5489 | 76.49K |
| Aug 11, 2026 | $0.5323 | $0.5476 | $0.515 | $0.5409 | 102.87K |
| Aug 10, 2026 | $0.515 | $0.54 | $0.515 | $0.5325 | 77.69K |
| Aug 7, 2026 | $0.49 | $0.54 | $0.465 | $0.5194 | 335.34K |
| Aug 6, 2026 | $0.5617 | $0.59 | $0.276 | $0.4717 | 451.68K |
| Aug 5, 2026 | $0.575 | $0.60 | $0.5611 | $0.5617 | 107.85K |
| Aug 4, 2026 | $0.58 | $0.60 | $0.572 | $0.575 | 168.18K |
| Aug 3, 2026 | $0.5685 | $0.5918 | $0.55 | $0.5842 | 102.25K |
| Jul 31, 2026 | $0.57 | $0.60 | $0.56 | $0.5685 | 163.28K |
| Jul 30, 2026 | $0.6125 | $0.632 | $0.5772 | $0.5803 | 205.28K |
| Jul 29, 2026 | $0.614 | $0.632 | $0.602 | $0.615 | 96.76K |
| Jul 28, 2026 | $0.61 | $0.6192 | $0.595 | $0.6149 | 192.02K |
| Jul 27, 2026 | $0.65 | $0.66 | $0.6157 | $0.6228 | 133.32K |
| Jul 24, 2026 | $0.6877 | $0.6925 | $0.65 | $0.6519 | 45.97K |
Latest SKYE news
The latest Smart Investors Daily articles mentioning SKYE.
Stock researchCompany · Overview
SKYE research
Overview
Company profile and research snapshot.
Company profile
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | Evercore ISI Group | Outperform | — |
| Jun 24, 2025 | JMP Securities | Market Outperform | — |
| Mar 21, 2025 | Citizens Capital Markets | Market Outperform | — |
| Mar 21, 2025 | Craig-Hallum | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 14, 2026
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Skye Bioscience, Inc. (SKYE) M&A Call August 14, 2026 10:00 AM EDTCompany ParticipantsPunit Dhillon - President, CEO & DirectorLisa Mary Anson - CEO...
Benzinga · Aug 14, 2026
Skye Bioscience To Acquire Redx Pharma; Combined Company To Operate As Fibrx Therapeutics With $125M Financing
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor
Yahoo · Jul 17, 2026
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
